
    
      Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous
      cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels
      of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will
      be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will
      be determined.

        -  Trial with medicinal product
    
  